Key Financial Performance - Quarter Ended September 30, 2026

Income Statement:

  • Revenue from operations: ₹6,819.87 million (compared to ₹5,879.80 million in Q2 FY26, 16% increase)
  • Other income: ₹199.17 million (compared to ₹147.20 million in Q2 FY26)
  • Total income: ₹7,019.04 million
  • Cost of materials consumed: ₹2,992.48 million
  • Employee benefits expense: ₹696.12 million
  • Depreciation and amortization expense: ₹218.24 million
  • Profit before tax: ₹2,619.74 million (51% increase from ₹1,741.37 million in Q2 FY26)
  • Tax expenses: ₹652.29 million (Current tax: ₹605.81 million, Deferred tax: ₹46.48 million)
  • Net profit: ₹1,967.45 million (51% increase from ₹1,300.26 million in Q2 FY26)
  • Basic EPS: ₹16.02 (compared to ₹10.60 in Q2 FY26)
  • Diluted EPS: ₹15.98 (compared to ₹10.58 in Q2 FY26)

Half Year Performance (April - September 2026)

Income Statement:

  • Revenue from operations: ₹13,224.01 million (compared to ₹11,898.26 million in H1 FY26)
  • Other income: ₹423.18 million (compared to ₹237.05 million in H1 FY26)
  • Total income: ₹13,647.19 million
  • Profit before tax: ₹4,741.97 million (41% increase from ₹3,371.18 million in H1 FY26)
  • Net profit: ₹3,568.21 million (42% increase from ₹2,515.61 million in H1 FY26)
  • Basic EPS: ₹29.06 (compared to ₹20.51 in H1 FY26)
  • Diluted EPS: ₹28.99 (compared to ₹20.46 in H1 FY26)

Balance Sheet Position as at September 30, 2026

Assets:

  • Total assets: ₹43,419.36 million (compared to ₹39,828.97 million as at March 31, 2026)
  • Property, plant and equipment: ₹10,105.11 million
  • Capital work-in-progress: ₹4,076.24 million (significant increase from ₹2,734.04 million)
  • Inventories: ₹7,827.66 million
  • Trade receivables: ₹9,881.87 million
  • Cash and cash equivalents: ₹254.35 million

Equity and Liabilities:

  • Equity share capital: ₹245.54 million (122,771,448 equity shares of ₹2 each)
  • Other equity: ₹36,067.32 million
  • Total equity: ₹36,312.86 million
  • Total liabilities: ₹7,106.50 million

Cash Flow Statement for Half Year Ended September 30, 2026

  • Cash generated from operations: ₹5,479.76 million
  • Income taxes paid: ₹882.85 million
  • Net cash from operating activities: ₹4,596.91 million
  • Cash used in investing activities: ₹3,708.81 million (mainly purchase of property, plant and equipment: ₹1,895.28 million and investments: ₹2,689.99 million)
  • Cash used in financing activities: ₹653.57 million (dividend paid: ₹613.86 million)
  • Net increase in cash and cash equivalents: ₹234.53 million

Significant Notes and Disclosures

1. Segment Reporting: The company operates in one reporting segment - Active Pharmaceutical Ingredient (API).

2. Employee Stock Options: As at September 30, 2026, 510,531 options were outstanding under Employee Stock Option Plan 2021, convertible into equivalent number of equity shares.

3. Share Capital Increase: The paid-up equity share capital increased to ₹245.54 million (122,771,448 equity shares) upon allotment of 32,000 equity shares pursuant to Employee Stock Option Scheme, 2021 during the quarter.

4. Exceptional Items: For the year ended March 31, 2026, exceptional items included ₹256.57 million for statutory impact of new labour codes (gratuity: ₹170.02 million, compensated absences: ₹86.55 million).

5. Subsidiary Formation: The company incorporated Alivus Life Sciences Do Brasil Ltda., a wholly owned subsidiary in Sao Paulo, Brazil on September 15, 2026. No investment has been made and the subsidiary has not commenced operations as of September 30, 2026.

6. Auditor Review: The financial results were subjected to limited review by statutory auditors Walker Chandlok & Co LLP, who expressed an unmodified review conclusion.